ClinicalTrials.gg
Sign In

Dwarfism, Pituitary clinical trials

The registry lists 252 studies for Dwarfism, Pituitary across more than 10 countries. 30 are recruiting or about to start. 202 of them are mainly about Dwarfism, Pituitary (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-10.

Get an email when these change. Save the Dwarfism, Pituitary studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Completed
163
Terminated
28
Status unknown
21
Recruiting
20
Not yet recruiting
7
Active, not recruiting
5

Phase

Phase 3
57
Phase 2
44
Phase 4
30
Phase 1
19
Early Phase 1
2

Where

United States
89
Germany
29
Italy
28
France
26
United Kingdom
25
Israel
16

Who runs them

Novo Nordisk A/S (27) · Pfizer (17) · Changchun GeneScience Pharmaceutical Co., Ltd. (13) · Merck KGaA, Darmstadt, Germany (9) · Federico II University (8) · Columbia University (8) · Versartis Inc. (7) · Ascendis Pharma Endocrinology Division A/S (6)

What is being tested here

Drugs under test in Dwarfism, Pituitary studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

DrugOpenPhase 3All
Human Growth Hormone32460
Ibutamoren326
Growth Hormone218
Inpegsomatropin101
GENSCI134101
Liraglutide101
Somapacitan038
Somavaratan037
Somatrogon036
Albusomatropin024

Coming up

7phase 3 studies under way
5studies finish main data collection within a year1 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

All 5, phase 3 first

Who these studies take

Of the 20 Dwarfism, Pituitary studies recruiting now, 5 (25%) set no upper age limit and 12 (60%) stop at 75 or younger. 11 (55%) take children under 18. 0 (0%) are for women only and 2 (10%) for men only; 4 (20%) take healthy volunteers.

Recruiting studies that take each age, of 20
AgeWomenMen
1011 (55%)11 (55%)
1811 (55%)13 (65%)
3011 (55%)13 (65%)
4011 (55%)13 (65%)
5010 (50%)12 (60%)
658 (40%)10 (50%)
756 (30%)8 (40%)
856 (30%)6 (30%)

Across all 252 studies, recruiting or not: 71% stop at 75 or younger and 61% at 65; 52% take children; 1% are for women only and 8% for men only; 19% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Dwarfism, Pituitary studies take

Of 19 phase 3 interventional studies under Dwarfism, Pituitary, half reached primary completion within 24 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 324 mo18–30 · 19 studies——
Observational85 mo54–102 · 30 studies——

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

Studies

Recruiting first, then most recently updated. Showing 50 of 252. Browse all 252 → or search them.